CHARACTERIZATION OF THE POSITIVE AND NEGATIVE INOTROPIC EFFECTS OF ACETYLCHOLINE IN THE HUMAN MYOCARDIUM

被引:33
作者
DU, XY
SCHOEMAKER, RG
BOS, E
SAXENA, PR
机构
[1] ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI,COEUR,CARDIOVASC RES INST, DEPT PHARMACOL, 3000 DR ROTTERDAM, NETHERLANDS
[2] ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI,COEUR,CARDIOVASC RES INST, DEPT THORAC SURG, 3000 DR ROTTERDAM, NETHERLANDS
关键词
ACETYLCHOLINE; ATRIUM AF-DX 116; HUMAN; HHSID (P-FLUOROHEXAHYDRO-SILADIFENIDOL HYDROCHLORIDE); MCN-A-343; MUSCARINIC RECEPTOR; MYOCARDIAL CONTRACTILITY; PIRENZEPINE; VENTRICLE;
D O I
10.1016/0014-2999(95)00384-W
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the human isolated myocardium, acetylcholine (10(-9) to 10(-3) M) elicited a biphasic inotropic effect (a decrease in the lower and an increase in the higher concentration range) in atrial and a positive inotropic effect in ventricular trabeculae. However, under conditions of raised contractility achieved by exposure to noradrenaline (10(-5) M), only negative inotropic effects were observed in both atria and ventricles. Atropine (10(-6) M), but not propranolol(10(-6) M), antagonized both positive and negative inotropic effects of acetylcholine, thus showing that the responses were mediated by muscarinic acetylcholine receptors. The use of subtype selective muscarinic receptor antagonists (10(-7) to 10(-5) M), pirenzepine (M(1) > M(3) > M(2)), AF-DX 116 (11-({2-[(diethyiamino)-methyl]-1-piperidyl}-5,11-dihydro-6H-pyridol[2,3-b][1,4]benzodiazepine-6-one base; M(2) > M(1) > M(3)) and HHSiD (p-fluorohexahydro-siladifenidol hydrochloride; M(3) greater than or equal to M(1) >> M(2)) revealed that the negative inotropic effect of acetylcholine in atrial as well as the positive inotropic effect in ventricular trabeculae were best antagonized by AF-DX 116 and not by pirenzepine, suggesting the involvement of the muscarinic M(2) receptor subtype, possibly linked to different second messenger systems. On the other hand, the positive inotropic effect of acetylcholine (10(-6) to 10(-3) M) in the atrial tissue, observed only in preparation with depressed contractility, was not effectively antagonized by either AF-DX 116 or HHSiD, but was significantly reduced by pirenzepine. Furthermore, the selective muscarinic M(1), receptor agonist McN-A-343 (4-(m-chlorophenylcarbamoyloxy)-2-butynyltrimethyl ammonium chloride; 10(-9) to 10(-3) M), which failed to significantly change the baseline contractility in either atrial or ventricular trabeculae, produced a positive inotropic effect in atrial preparations when contractility had been depressed by prior treatment with acetylcholine (10(-9) to 10(-7) M). This effect of McN-A-343 was effectively antagonized by pirenzepine (10(-5) M). These data show that, besides the muscarinic M(2) receptor mediating both negative (atria) and positive (ventricle) inotropic effects, muscarinic M(1) receptors, capable of reversing depressed atrial contractility, are present in the human heart.
引用
收藏
页码:119 / 127
页数:9
相关论文
共 47 条
[1]   COUPLING OF M-CHOLINOCEPTORS AND A(1) ADENOSINE RECEPTORS IN HUMAN MYOCARDIUM [J].
BOHM, M ;
GIERSCHIK, P ;
SCHWINGER, RHG ;
UHLMANN, R ;
ERDMANN, E .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (05) :H1951-H1958
[2]  
BRODDE OE, 1992, BASIC RES CARDIOL, V87, P1
[3]  
BROWN JH, 1984, J BIOL CHEM, V259, P3777
[4]   MUSCARINIC RECEPTORS - CHARACTERIZATION, COUPLING AND FUNCTION [J].
CAULFIELD, MP .
PHARMACOLOGY & THERAPEUTICS, 1993, 58 (03) :319-379
[5]   COMPARISON OF BUTYRYLCHOLINESTERASE AND ACETYLCHOLINESTERASE [J].
CHATONNET, A ;
LOCKRIDGE, O .
BIOCHEMICAL JOURNAL, 1989, 260 (03) :625-634
[6]  
DEIGHTON NM, 1990, N-S ARCH PHARMACOL, V341, P14
[7]   SIMULTANEOUS ANALYSIS OF FAMILIES OF SIGMOIDAL CURVES - APPLICATION TO BIOASSAY, RADIOLIGAND ASSAY, AND PHYSIOLOGICAL DOSE-RESPONSE CURVES [J].
DELEAN, A ;
MUNSON, PJ ;
RODBARD, D .
AMERICAN JOURNAL OF PHYSIOLOGY, 1978, 235 (02) :E97-E102
[8]   PHARMACOLOGICAL PROFILE OF SELECTIVE MUSCARINIC RECEPTOR ANTAGONISTS ON GUINEA-PIG ILEAL SMOOTH-MUSCLE [J].
DOODS, HN ;
ENTZEROTH, M ;
ZIEGLER, H ;
MAYER, N ;
HOLZER, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 253 (03) :275-281
[9]  
DOODS HN, 1987, J PHARMACOL EXP THER, V242, P257
[10]  
DORJE F, 1991, J PHARMACOL EXP THER, V256, P727